

# FDA-ASCO Geriatric Oncology Workshop

## Session 3. Leveraging research designs for real-world patients: Real-world evidence

November 6, 2017

ASCO's CancerLinQ®: Real-  
world insights to drive quality  
improvement and discovery

**Robert S. Miller MD, FACP, FASCO**  
American Society of Clinical Oncology  
Vice President and Medical Director  
CancerLinQ




---

# ASCO & CancerLinQ




- Leading professional organization representing physicians caring for those with cancer
- >44,000 members from 100+ countries
- Mission: Conquering cancer through research, education, and promotion of the highest quality patient care
- Not-for-profit subsidiary of ASCO
- Dedicated staff and governing board
- Mission: Empowering the oncology community to improve quality of care and patient outcomes through transformational data analytics

## Getting to the data



**97%**  
of patient data  
**locked away** in unconnected  
files and servers



QI



**Measure and benchmark  
quality of care**

Research



**Unlock, assemble, and analyze  
de-identified cancer patient  
medical records**

QI



**Provide guidance by identifying  
the best evidence-based  
course of care**


Research



**Uncover patterns  
to generate knowledge**



# Overview of CancerLinQ data assets and flows



## CancerLinQ progress to date

**110**

practices/  
cancer centers  
(92 signed BAAs)

**30**

implementations  
in progress

**37**

active sites

**12**

source systems  
represented

**~2,500**

oncologists

**>550K**

active cancer  
patient records

---

# What is CancerLinQ Discovery™?

**An extension of CancerLinQ's QI-focused database designed to support hypothesis-based research**

1. Key structured data elements → additional editorial/curation effort to ensure that those data elements exist in a canonical form
2. Uses natural language processing and manual curation to extract additional data from unstructured data
3. Initial area of focus: non-small cell lung cancer
4. Third parties can submit data requests to the CancerLinQ Discovery Research & Publications Committee for approval



[www.cancerlinq.org/research-database](http://www.cancerlinq.org/research-database)

# Data Access Process



## Submit Request

- Two part process: data request form & on-line upload and submission
- Initial CancerLinQ Discovery™ request screening



## High-level Data Sufficiency Review

- CancerLinQ Discovery™ data availability & quality check — data fit for purpose
- Initial project data specifications and cost estimates determined



## CancerLinQ Discovery™ Research & Publications Committee Review

- Full review and consensus decision making process
- Committee may request additional information from data requester



## Decision on CancerLinQ Discovery™ Request

- Requester notified of decision on submitted data request
- Successful requests move forward to identify contract terms, project cost, and provisions of data



## Selected adjuvant trials from the literature

- MOSAIC (JCO 2009) – 5FU/leucovorin +/- oxaliplatin
  - Stage II/III colon cancer
  - Median age FOLFOX4 arm = 61      **CLQ median age = 68**
  - Age > 65 = 35.6% (pts > age 75 not eligible)      **CLQ age 60-80 = 52%**
- CheckMate 238 (NEJM 2017) – nivolumab vs. ipilimumab
  - Stage IIIB, IIIC, or resected Stage IV melanoma
  - Median age (range): nivo = 56 (19-83), ipi = 54 (18-86)      **CLQ median age = 64**
  - Age  $\geq$  75: nivo = 3.8%, ipi = 2.9%      **CLQ age >70 = 36%**
- IALT (NEJM 2004) – cisplatin-based chemo vs. observation
  - Stage I-III non-small cell lung cancer s/p resection
  - Median age (range) chemo arms = 59 (27-77)      **CLQ median age = 71**

# Limitations of real-world evidence in studying the geriatric population

- Data limited to what is available in the EHR source
- Many important oncologic concepts not captured in structured data fields
- Elements of geriatric assessment domains sparsely represented:
  - Functional status ✗
  - Cognitive function ✗
  - Comorbidities ✓ *as ICD9/10 codes*
  - Psychological state ✗
  - Nutritional status ✗
  - Social support ✓ *marital status alone*
- Outcomes of importance to older adults (e.g., impact of Rx on function or cognition) can only be obtained through curation